News

15 March 2016 Dr Sam Hupert, CEO and Co-Founder, Pro Medicus, was one of the invited speakers at the 2016 ASX Spotlight Series New York. The ASX Spotlight Series is a targeted international investor conference, providing investors an opportunity to hear from senior executives from ASX-listed companies. In the below video interview, Dr Hupert provides a Pro Medicus overview, while also discussing market potential, competitive forces, financial performance and growth opportunities.      

19 February 2016  |   CEO on H1 Results - Acrobat pdf 493k   Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, discussing the latest PME Interim Results.        

19 February 2016  |  Company Announcement Pro Medicus Limited 2016 Interim Results - Acrobat pdf 178k Key Points: After-tax profit of $2.94 million – up 82.9% Revenue of $14.28 million – up 65.3% Underlying profit from operations $2.82 million – up 188.5% Year-end cash reserves increased to $16.19 million Increased interim dividend of 1.5c per share (unfranked) Continuing strong inroads into North American market, including $11 million contract with Allegheny Health Network in Pittsburgh area Large contract signed in Europe Successfully completed implementation of 3 previously announced contracts Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a first half after-tax profit of $2.94 million for the six months to 31 December 2015 – an increase of $1.33 million (82.9%) on the previous corresponding period. Revenue for the six months was $14.28 million – a 65.3% increase on the previous corresponding period. Underlying profit from operations was $2.82 million compared to $0.98 million for the previous corresponding period – an increase of 188.5%. The company's cash reserves were $16.19 million at the end of the period, an increase of $3.26 million. The company remains debt-free and announced an increased interim dividend of 1.5c per share (unfranked). During the period the company made several key announcements – including a $11 million contract with the Allegheny Health Network, a large health system in the Pittsburgh area, and a $3 million deal with a large hospital network in Germany. These announcements further underlined Pro Medicus’ leading position in imaging technology and its gathering acceptance in international health markets. Dr Sam Hupert, Pro Medicus Chief Executive Officer, said the increase in revenue during the period was largely a result of transactional fees from the implemented contracts beginning to take

16 November 2015; Company Announcement Pro Medicus Signs Large German Hospital - Acrobat pdf 131k Key Points Large German government hospital to use Visage 7 technology throughout its’ diagnostic imaging facilities Cross-regional diagnostic image access with other key hospitals across Germany Five-year capital deal, with base value to PME of A$3 million Deconstructed PACS® gaining momentum in Europe Expands Visage footprint in key German hospital market Leading health imaging company, Pro Medicus Limited [ASX: PME] today announced its’ wholly owned European subsidiary, Visage Imaging GmbH, has signed a A$3 million five-year contract with one of the largest government run hospitals in Germany. As part of the deal, the hospital will implement Visage 7 as the central component of a Deconstructed PACS® strategy, integrating it to the hospitals’ recently selected workflow solution, and several existing DICOM archives. A testament to the flexibility of Visage 7, most of the diagnostic workstations will be installed on Apple Mac computers running OS X. Visage 7 “satellite” servers will also be implemented at three other government sites in northern and southern Germany to facilitate a new enhanced level of image sharing with these sites for cross-regional diagnostic imaging access. “Given the significant pressures on modern Radiology, we’re looking to Visage to provide a step-change in our historical capabilities,” said the department’s chief radiologist. “Visage’s speed and regional architecture will enable our physicians to have rapid access to images, from any of our hospitals, or wherever required to care for our soldiers and civilian patients. Visage also represents a fundamental change in how a system is configured. By adopting a modular strategy we will be able to seamlessly scale over time, while staying technologically ahead of our ever-growing volume of imaging data”.

5 October 2015 The Business's Ticky Fullerton interviewed Dr Sam Hupert, CEO and Founder of Pro Medicus, about "making waves and locking in contracts in the US with its Visage medical imaging technology."  Some additional key quotes from the interview include the following: "There's been a fundamental change in the way this technology is being purchased, and we're very much in that sweet spot…" "We can visualize massive data sets… on standard Internet… in 2-to-3 seconds" "We believe we're just scratching the surface in that market [the U.S.]." "A number of forces in the market have pushed the large health institutions to look at alternatives, and those forces are the ability to tie everything into one record — not just radiology — and clearly the size of the data sets the new radiology equipment is creating, and that favors our technology." "Their technology [legacy vendors] is not as well suited to the new paradigm as ours." Click on the video for the complete interview.

24 September 2015; Company Announcement Pro Medicus Signs AHN - Acrobat pdf 88k Key Points: Allegheny Health Network (AHN) to use Pro Medicus’ Visage 7 technology for primary diagnoses and clinical distribution of medical images Five-year deal with base value to PME in excess of A$11 million AHN is a subsidiary of Highmark Health, which is Blue Cross Blue Shield-affiliated The Highmark Health enterprise is the 3rd largest health care delivery & financing system in America Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned US subsidiary, Visage Imaging Inc, has signed an A$11 million five-year contract with Allegheny Health Network (“AHN”). AHN is a subsidiary of Highmark Health, the 3rd largest health care delivery & financing system in America, which is affiliated with Blue Cross Blue Shield. The contract will see Pro Medicus’ Visage 7 technology used for primary diagnosis across AHN, as well as clinical distribution of diagnostic images to 2,800 physicians throughout the AHN network via a single point of access to the AHN EHR. AHN is a unified system comprised of eight hospitals, including Allegheny General Hospital, Allegheny Valley Hospital, Canonsburg Hospital, Forbes Hospital, Jefferson Hospital, Saint Vincent Hospital, Westfield Memorial Hospital and West Penn Hospital. AHN’s integrated care portfolio has an urban, academic and community focus, including over 2,000+ beds and more than 200 locations. AHN is one of the largest health networks in the Pittsburgh metro area, providing care to 29 Pennsylvania counties, as well as portions of New York, Ohio and West Virginia. “Visage 7’s prominence in enterprise imaging exemplifies the world class capabilities that we’re bringing to AHN,” said Dr Paul M. Kiproff, Chair, AHN Department of Radiology.

PME CEO on Full-Year Results Open Briefing - Acrobat pdf 425k 21 August 2015 Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, discussing the latest PME Full-Year Results.    

Pro Medicus Limited Full-Year Results 2014-15 - Acrobat pdf 146k 21 August 2015 Key Points: Profit up 113.2% to $3.22 million Revenue up 21.7% to 17.58 million US operations key driver of profit increase Cash balance $12.94 million after tax on Amira sale and dividends Company remains debt-free 1c per share (unfranked) final dividend making total for year of 2c per share (unfranked) Leading medical imaging company, Pro Medicus Limited [ASX: PME] today announced its full- year results for the year to 30 June 2015. Profit for the year was $3.22 million, up 113.2% on the previous corresponding period. Annual revenue was $17.58 million, up 21.7% on the previous corresponding period. Margins increased as a result of US contract revenue as well as a positive currency impact. At year end, the company’s cash reserves were $12.94 million after paying $3.74 million tax on the Amira sale announced in 2012 and dividend payout of $2.00 million. Directors declared a final unfranked dividend of 1c a share, making a total for the year of 2c a share, unfranked. Pro Medicus Chief Executive Officer Dr Sam Hupert said 2014-15 was a year in which Pro Medicus built on the momentum from the previous year. The company made several key announcements which further underlined the leading position of the company’s imaging technology and its gathering acceptance across international health markets. 20 November 2014 – WellSpan Health Pro Medicus announced the signing of an A$8 million seven-year contract with WellSpan Health, a large regional health network in the northeastern United States. Under the contract, WellSpan agreed to use Pro Medicus’ Visage 7 technology as a core component of its new enterprise imaging platform for at least the next seven years. 12 January

 Pro Medicus Receives FDA Clearance for Visage Ease Pro - Acrobat pdf 105k 19 May 2015 Leading imaging IT provider, Pro Medicus Limited [ASX: PME], today announced its wholly-owned US subsidiary Visage Imaging Inc has received US Food and Drug Administration (FDA) 510 (k) clearance for its Visage Ease Pro mobile app technology. Visage Ease Pro has been certified for diagnostic interpretation of all imaging modalities apart from mammography which requires higher screen resolution than current mobile devices can support. “With Visage Ease, our current mobile app, we lead the pack in terms of speed and functionality for review access of images. Our new Pro version has raised the bar even further. Incorporating the ability to quickly check the calibration of the screen of an iOS device means that radiologists and allied physicians that require full diagnostic capability on the go can now have it on their mobile device. This enables them to securely interpret images no matter how large they are anywhere using Visage technology.” Visage Ease Pro includes numerous image manipulation features, display of non-DICOM (and non-diagnostic) images such as photos, support for recording voice memos, and the ability to upload photo attachments to studies on Visage 7. Dr Hupert said: “FDA clearance represented the culmination of 12 months of regulatory negotiations. We join only a handful of other mobile applications that have received FDA approval but we believe ours is the only FDA approved mobile solution that is an integral part of a total enterprise imaging platform.” Dr Hupert also said that the technology has been approved for use in Australia by the Therapeutic Goods Administration, as well as in Canada and Europe. “This approval worldwide represents further validation of the extent and functionality

Pro Medicus Signs A$9.5 Million Deal with University of Florida Health Network - Acrobat pdf 128k 21 April 2015 Key Points: UF Health to use Visage 7 technology for primary diagnosis and clinical distribution of medical images Seven-year deal, with base value to PME of A$9.5 million Significant win at prestigious university/academic institution Hybrid of capital and transaction-based models with potential upside Leading imaging IT provider, Pro Medicus Limited [ASX: PME] today announced its wholly owned US subsidiary, Visage Imaging Inc., has signed a A$9.5 million seven-year contract with University of Florida Health — a large university health system in Northern Florida. The deal furthers the penetration of Visage 7 technology in the university/academic hospital space, a key area of the North American enterprise imaging market. The contract will see Pro Medicus’ Visage 7 technology used for primary diagnosis across UF Health, as well as clinical distribution of diagnostic images to thousands of physicians throughout the UF Health care network. UF Health comprises two health campuses: UF Health Shands Hospital in Gainesville, FL, incorporating UF Health Shands Cancer Hospital and UF Health Shands Children’s Hospital, and UF Health Jacksonville in Jacksonville, FL. UF Health provides comprehensive high-quality patient care, from primary care and family medicine to subspecialty tertiary and quaternary services for patients with highly complex medical conditions. The faculty of the UF College of Medicine includes internationally recognised physicians whose expertise is supported by intensive research activities. Each year patients come to UF Health from around the world, across the US, and from all 67 Florida counties. “After 18 - 24 months of careful analysis by a team of technologists, physicists, radiologists and clinical providers we are happy to be working with Visage to provide the visualization